TSX runs higher on rate cut expectations
NEW YORK - Anavex Life Sciences Corp. (NASDAQ:AVXL), currently valued at $954 million, reported that its oral Alzheimer’s treatment candidate blarcamesine demonstrated up to 84.6 weeks (19.5 months) of "time saved" in disease progression for early-start treatment patients, according to data presented at the Alzheimer’s Association International Conference in Toronto. While the stock has seen a 12% decline over the past week, InvestingPro data shows impressive returns of over 64% in the past year.
The findings come from the ATTENTION-AD open-label extension trial, which followed a 48-week double-blind study for a combined duration of up to 192 weeks in patients with early Alzheimer’s disease. According to InvestingPro analysis, the company maintains a strong financial position with more cash than debt and a healthy current ratio of 6.74, providing adequate resources for its clinical programs.
In the intent-to-treat population, early-start treatment showed significant advantages over delayed treatment in both cognition (ADAS-Cog13) with a difference of -3.83 points (P = 0.0165) and function (ADCS-ADL) with a difference of +4.30 points (P = 0.0206) at Week 192.
A genetically identified population called ABCLEAR2, representing approximately 71.7% of the global population, showed even greater improvements with differences of -5.43 points in cognition (P = 0.0035) and +9.50 points in function (P
"Prespecified delayed-start analysis indicate disease-modifying effect of oral blarcamesine and highlight the importance of early and continued long-term treatment of chronic Alzheimer’s disease," said Dr. Marwan Noel Sabbagh, Professor of Neurology and Chairman of Anavex’s Scientific Advisory Board.
The company also presented data suggesting blarcamesine works by restoring impaired autophagy, a cellular cleaning mechanism that precedes the formation of amyloid-beta and tau proteins associated with Alzheimer’s disease.
The drug demonstrated a favorable safety profile with no treatment-related deaths, according to the press release statement. Common adverse events included mostly mild to moderate transient dizziness.
Blarcamesine is administered as a once-daily oral pill, which the company suggests could provide a more accessible treatment option for patients with early Alzheimer’s disease. With analyst price targets ranging from $15 to $46 per share, the market appears optimistic about Anavex’s potential. For deeper insights into Anavex’s financial health and growth prospects, investors can access comprehensive analysis through InvestingPro’s detailed research reports, which cover over 1,400 US stocks.
In other recent news, Anavex Life Sciences Corp. reported a net loss of $11.2 million, or $0.13 per share, for the second quarter of 2025. Despite this financial result, the company is experiencing positive investor sentiment, partly due to developments in its treatment programs for Alzheimer’s and schizophrenia. Additionally, Anavex announced that its stockholders have approved an amendment to the 2022 Omnibus Incentive Plan. This amendment increases the number of shares authorized for issuance by 4 million and establishes a minimum vesting period of one year for all awards, with specific exceptions. The plan also introduces measures to prohibit certain practices related to share recycling and net share counting. Furthermore, the company has extended the contracts of its CEO, Christopher Missling, and its Principal Financial Officer. Dr. Missling’s contract, effective July 5, 2025, will now run through July 5, 2028, with an annual base salary of $800,000. These developments reflect Anavex’s ongoing strategic initiatives and corporate governance measures.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.